CASE REPORT

A low-grade astrocytoma in a sixteen-year-old boy with a 7q11.22 deletion

Francoise S. van Kampen¹, Marianne E. Doornbos¹, Monique A. van Rijn² & Yolande den Bever³

¹Department of Paediatrics, Albert Schweitzer Hospital, Dordrecht, The Netherlands
²Department of Neurology, Albert Schweitzer Hospital, Dordrecht, The Netherlands
³Department of Clinical Genetics, Erasmus University Hospital, Rotterdam, The Netherlands

Correspondence
Franciscus Vlietland Group Vlietlandplein 2
Postbus 215 3100 AE Schiedam
Tel: (0031)108939393
E-mail: cois24@hotmail.com

Key Clinical Message
We report a patient with developmental delay due to germline AUTS2 mutation who developed a low-grade astrocytoma. While the contribution of this mutation to the pathogenesis of the tumor is not known at this time, a role of AUTS2 in deregulation of PRC1 can be a part in tumorigenesis of a brain tumor.

Keywords
AUTS2, brain tumor, neurologic, pediatric.

Background
In this case report, we describe a first patient with a low-grade astrocytoma and a deletion in the AUTS2 gene. Mutations in (parts of) the autism susceptibility candidate 2 (AUTS2) are described in case reports and further explored in animal models. The hypothesis is that the AUTS2 protein has an important role in axon guidance, dendrite elaboration, synaptogenesis or related aspects of neuronal development, but the exact function is not known. The phenotype has a wide range of features with intellectual disability, autism, and dysmorphic features. A role in tumorigenesis of brain tumors is not yet proved.

Low-grade gliomas are the most common central nervous system tumors in childhood. Benign cerebellar astrocytomas are most prevalent, accounting for 15–25% of all central nervous system tumors [1, 2]. Diffuse astrocytomas account for approximately 5% of all tumors in children aged 0–14 years [3]. Malignant transformation in most low-grade tumors is rare [2]. First treatment of choice is complete resection of the tumor. After surgery, the long-term results are good.

With time more is known about tumorigenesis. Mitogen-activated protein kinase (MAPK) pathway activation drives the formation of most low-grade gliomas (LGG). The most common mechanism of a MAPK pathway activation in LGG’s is a tandem duplication on chromosome 7q34. In addition, deletions in 7q34 are described [4]. Astrocytomas are occasionally described in Noonan, Turner, Lynch syndrome, and neurofibromatosis.

We present a patient with a low-grade astrocytoma and a deletion of chromosome 7q11.22.

Clinical Case Report

Our patient is the fifth child of nonconsanguineous Dutch parents. His eldest sister has ADHD and a mild intellectual disability (ID). His other sister and two brothers are healthy. The son of his father’s sister has a coloboma of both eyes and a mild mental retardation.

Our patient was born term after normal pregnancy and no complications during and after delivery. He was diagnosed with a coloboma of the left eye in the neonatal period and at the age of 5 years, he was diagnosed with a mild intellectual disability (IQ 72) and he is following special education.

At the age of 12 years, he was evaluated for a small stature which was related to a late puberty. His puberty
started at the age of fifteen and he reached a normal height.

In 2013, he had his first generalized tonic-clonic epileptic seizure treated in the emergency department.

In the past 6 months, he had episodes of bilateral tinnitus with dizziness and difficulty speaking. During these episodes, duration of 30 sec and approximately three times a week, he turns his head to the left side and parents noticed an impairment of consciousness. After the episode, he complains of nausea and headache. These episodes were diagnosed as complex partial seizures.

On physical examination, we found mild dysmorphisms: hypotelorism, a broad forehead, a broad nose bridge, a full nose tip, and full lips. He has long feet and arms with a cubitus valgus.

We performed an EEG and a MRI of the brain. The EEG showed mild diffuse slowing of the right hemisphere, but no epileptic activity. The MRI of the brain showed a hyperintense lesion on T2 and flair images in the right temporal lobe, with enhancement after admission of gadolinium. The radiological differential diagnosis included ganglioglioma, DNET, or low-grade astrocytoma (Fig. 1).

Consequently, he was operated in an academic hospital and the tumor was completely removed. Pathology shows a diffuse infiltrating low-grade astrocytoma (Fig. 2).

No adjuvant therapy was given.

A MRI of the brain 6 months after surgery did not show residual tumor or recurrence of the tumor. After resection of the astrocytoma, the patient no longer suffered from seizures and a year after surgery, the antiepileptic drugs were successfully stopped. Follow-up will be every 9 months until at least 5 years after the surgery.

**Results**

The combination of a coloboma, a mild intellectual disability, a late puberty, mild dysmorphisms, and an epileptic seizure could well have a genetic cause, such as CHARGE syndrome. Tumors including a low-grade astrocytoma can be part of various syndromes.

We performed a SNP-array on total genomic DNA extracted from leucocytes. The Illumina Human Cyto 12-SNP genotyping array was used in combination with the Illumina iScan Control and the Nexus Copy Number 7.0

Figure 1. (A) Flair image with hyperintense lesion in the right temporal lobe (indicated by an arrow). (B) Flair image with hyperintense lesion in the right temporal lobe (indicated by a red line).
A deletion of 457 kb in band 7q11.22 (chr7: 68,910,981–69,367,635) was found. This loss includes 61 probes and a part of AUTS2 including some exons (exon 2, 3 and 4).

In June 2015, we performed a whole-exome sequencing also on total genomic DNA extracted from leucocytes for genes involved with ID, epilepsy, autism, and neuronal migration disorders. The WES did not show any causative mutations.

Pathology of the tumor shows a low-grade diffuse astrocytoma, IDH-wildtype, WHO grade 1 (corresponding to the 2016 WHO Classification system for CNS tumors).

Further genetic testing shows a point mutation in the BRAF v600e gene. This mutation is seen in <10% of all pilocytic astrocytomas.

**Discussion**

Autism susceptibility candidate 2 (AUTS2) is located on chromosome 7q11.22 and spans 1.2 MB of the genomic DNA. AUTS2 consist of 19 exons where the first half of the gene (exon 1–6) has relatively large introns and the second half (exons 7–19, C-terminus) has smaller clustered introns. The exact function of AUTS2 is unknown, but deletions in the AUTS2 region gives a wide range of syndromic phenotypes, including intellectual disability, autism, microcephaly, short stature, hypotonia, cerebral palsy, and dysmorphic features. The phenotype can be subtle, and the severity of the syndrome is highly variable. Furthermore, the location and the type of deletion are important for the resulting phenotype, with a more severe phenotype with deletions in the C-terminus [5]. A recent study of Beunders et al. described 13 patients (including six adults) with AUTS2 syndrome with unique pathogenic deletions scattered around the AUTS2 locus and confirm a phenotype–genotype correlation [6].

The AUTS2 protein also plays an important role in neurodevelopment. Earlier studies with knockdown AUTS2 zebrafish shows a reduction in motor and sensory neurons in the spinal cord and developing neurons in regions that include the midbrain and cerebellum, which resulted in reduced movement and decreased response to touch [5, 7]. Mouse studies show that there is expression of AUTS2 in developing neurons in the frontal cortex and cerebellum. This suggests that AUTS2 could be important for migration, axon guidance, dendrite elaboration, synaptogenesis, or related aspects of neuronal development [8].

The study of Hori et al. suggests that AUTS2 may also have a cytoplasmic role in cytoskeletal regulation, in addition to its nuclear function, and indicate that cytoplasmic AUTS2 is involved in cortical neuronal migration [9]. They did not observe abnormal apoptosis or proliferation of cells in any of their AUTS2 mutant mouse brains.

Gao et al. show a role for AUTS2 in modulating the role of polycomb repressor complex 1 (PRC1) from a repressive function to transcription stimulation in the AUTS2–PRC1 complex. In this way, AUTS2 plays a role in regulation of neuronal gene expression through promoter association. Their hypothesis is that changes in AUTS2 result in reduced neuronal gene expression trough the AUTS2–PRC1 complex and can give different developmental defects [10]. Polycomb group proteins plays an important role in neurodevelopment, but deregulation can lead to oncogenesis. Deregulation of PRC1 plays a role in formation and progression of glioblastomas [11]. BMI1 or polycomb group ring finger protein 4, which is part of PRC1, has a role in the suppression of p16INK4a [12]. Lack of expression of p16INK4a next to a BRAF v600e mutation, gives less senescence and more tumor growth, where a BRAF v600e mutation alone is sufficient to promote only some aspects of oncogenic transformation [13]. Probably changes in the AUTS2 gene can result in deregulation of PRC1 through changes in the AUTS2–PRC1 complex.

The possibility that this patient has two rare diseases which are not linked to each other can not be fully excluded, but may be less likely.

**Conclusions**

This is the first case description of a patient with a mutation in the AUTS2 gene and a brain tumor, in this case a low-grade astrocytoma. Both the exact function of the
AUTS2 protein and the neurodevelopment of low-grade gliomas are not yet known. There is a possible role for the AUTS2 gene in the development of low-grade gliomas via migration, axon guidance, dendrite elaboration, synaptogenesis, or related aspects of neuronal development. There may also be a role in tumorigenesis for the AUTS2 protein by deregulation of PRC1.

Authorship

FSK: was the main author and writer of the article. MED: was the doctor hereditary and congenital anomalies, diagnosed our patient with a syndromal problem, and the mentor of the main author. MAR: was the head practitioner of our patient and reviewer of the article. YB: was the clinical geneticist and performed all genetic test and checked our hypothesis.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Bonfield, Christopher M., and Paul Seinbok. 2015. Pediatric cerebellar astrocytoma: a review. Childs Nerv. Syst. 31:1677–1685.
2. Baker, S. J., D. W. Ellison, and D. H. Gutmann. 2015. Pediatric gliomas as neurodevelopmental disorders. Glia 64:879–895.
3. Johnson, K. J., J. Cullen, J. S. Barnholtz-Sloan, Q. T. Ostrom, C. E. Langer, M. C. Turner, et al. 2014. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol. Biomarkers Prev. 23:2716–2736.
4. Roth, J. J., M. Santi, A. N. Pollock, B. N. Harding, L. B. Rorke-Adams, L. S. Took, et al. 2015. Chromosome Band 7q34 Deletions Resulting in KIAA1549-BRAF and FAM131B-BRAF Fusions in Pediatric Low-Grade Gliomas. Brain Pathol. 25:182–192.
5. Bedogni, F., R. D. Hodge, B. R. Nelson, E. A. Frederick, N. Shiba, R. A. Daza, et al. 2013. Exonic deletions in AUTS2 cause a syndromic form of intellectual disability and suggest a critical role of the C-terminus. Am. J. Hum. Genet. 92:210–220.
6. Beunders, G., J. van de Kamp, P. Vasudevan, J. Morton, K. Smets, T. Kleefstra, et al. 2016. A detailed clinical analysis of 13 patients with AUTS2 syndrome further delineates the phenotypic spectrum and underscores the behavioural phenotype. J. Med. Genet. 53:523–532.
7. Oksenberg, N., L. Stevison, J. D. Wall, and N. Ahituv. 2013. Function and regulation of AUTS2, a gene implicated in autism and human evolution. PLoS Genet. 9: e1003221.
8. Bedogni, F., R. D. Hodge, B. R. Nelson, E. A. Frederick, N. Shiba, R. A. Daza, et al. 2010. Autism susceptibility candidate 2 (Auts2) encodes a nuclear protein expressed in developing brain regions implicated in autism neuropathology. Gene Expr. Patterns 10:9–15.
9. Hori, K., T. Nagai, W. Shan, A. Sakamoto, S. Taya, R. Hashimoto, et al. 2014. Cytoskeletal regulation by Auts2 in neuronal migration and neuritogenesis. Cell Rep. 9: 2166–2179.
10. Gao, Z., P. Lee, J. M. Stafford, M. von Schimmelmann, A. Schaefer, and D. Reinberg. 2014. Auts2 confers gene activation to Polycomb group proteins in the CNS. Nature 516:349–354.
11. Hu, Q., W. Wu, A. Zeng, T. Yu, F. Shen, E. Nie, et al. 2016. Polycomb group expression signatures in the malignant progression of gliomas. Oncol. Lett. 13: 2583–2590.
12. Wang, W., Y. Zhu, K. Huang, Y. Shan, J. Du, X. Dong, et al. 2017. Suppressing p16INK4a and p14ARF pathways overcomes apoptosis in individualized human embryonic stem cells. FASEB J. 31:1130–1140.
13. Raabe, E. H., K. S. Lim, J. M. Kim, A. Meeker, X. G. Mao, G. Nikkhah, et al. 2011. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 17:3590–3599.

© 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.